VEGF inhibitors | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

15,148 results for “VEGF inhibitors”

Trials

View all 7129 →

Photobiomodulation for the Treatment of Diabetic Macular Edema

16 participants · First posted May 29, 2015

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

53 participants · First posted Jan 20, 2021

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.

150,000 participants · First posted Jan 29, 2018

Drugs

View all 3367 →

VEGF (NIH)

VEGF (Trophogen)

Neovasculgen

Organizations

View all 11 →

Outlook Therapeutics

United States

KalVista Pharmaceuticals

United States

Exelixis, Inc.

United States

News

View all 4641 →

FDA Grants Fast Track Designation to PD-1/VEGF Bispecific Antibody in NSCLC

FDA Grants Fast Track Designation to OncoC4's PD-1/VEGF Bispecific Cesalatamig for PD-(L)1-Refractory NSCLC

Ramucirumab Plus Somatostatin Shows Promise in Advanced Neuroendocrine Tumors with 14.2-Month PFS

Page 1 of 1515